William Blair Reiterates “Outperform” Rating for Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX)

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX)‘s stock had its “outperform” rating reiterated by research analysts at William Blair in a research note issued to investors on Wednesday,RTT News reports. William Blair also issued estimates for Telix Pharmaceuticals Limited American Depositary Shares’ FY2027 earnings at $1.44 EPS.

Separately, UBS Group raised their price target on Telix Pharmaceuticals Limited American Depositary Shares from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, January 27th.

Telix Pharmaceuticals Limited American Depositary Shares Stock Performance

NASDAQ:TLX opened at $16.99 on Wednesday. Telix Pharmaceuticals Limited American Depositary Shares has a 12-month low of $14.01 and a 12-month high of $30.36. The business has a fifty day moving average of $17.42.

About Telix Pharmaceuticals Limited American Depositary Shares

Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.